Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
565 hedge funds and large institutions have $33.4B invested in Alexion Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 240 increasing their positions, 194 reducing their positions, and 61 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 240 | Existing positions reduced: 194
6% less call options, than puts
Call options by funds: $121M | Put options by funds: $129M
8% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 61
2% less funds holding
Funds holding: 578 → 565 (-13)
6% less capital invested
Capital invested by funds: $35.6B → $33.4B (-$2.14B)
61% less funds holding in top 10
Funds holding in top 10: 18 → 7 (-11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$344M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$162M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$122M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$111M |
| 5 |
Millennium Management
New York
|
+$102M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$447M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$249M |
| 3 |
JP Morgan Chase
New York
|
-$182M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$122M |
| 5 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
-$118M |
ALXN Hedge Fund Activity: Q1 2015 in Review
565 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2015, worth a combined $33.4B — down 6% from $35.6B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of ALXN and 56 opened new positions — a net loss of 5 holders — while 194 trimmed existing stakes and 240 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $344M. The largest seller was Fidelity Investments, cutting an estimated $447M.
- 565 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2015, down from 578 in Q4 2014.
- Funds reported $33.4B of Alexion Pharmaceuticals stock for Q1 2015, down 6% quarter-over-quarter.
- 56 funds opened new Alexion Pharmaceuticals positions in Q1 2015 and 61 closed out, a net change of -5 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2015 was T. Rowe Price Associates, an estimated $344M added.
- The largest Alexion Pharmaceuticals seller in Q1 2015 was Fidelity Investments, an estimated $447M sold.
Based on aggregated 13F filings for Q1 2015.